BRS leads the biotechnology industry in developing safe and effective stem cell-based therapeutics for a number of indications that reduce patients’ quality of life, and shorten their life spans. Our focus is on conditions that are particularly debilitating and that lack effective therapies, such as neurodegenerative diseases including ALS, dementia, and glaucoma. At BRS we continue to focus on advancing therapeutics that are the first and best of their kind, significantly improving patients’ lives through the development of therapeutics that mimic and augment the powerful stem cell-based natural healing processes innate to the human body.

Beginning in my days as a research bioengineer at UC Berkeley and professor of Neuroscience at UCSD in the 1990s, my desire has been to develop a “Systems Therapeutic” (Maguire, 2014; 2016) based on reverse engineering stem cell processes in the human body. Our methodology at BRS, which evolved from these early studies at Berkeley and UCSD, is revolutionary and powerful and is called S²RM® technology. Stem cell released molecules (SRM) are the multitude of molecules released from a stem cell. For the purpose of maintaining and healing tissue, the SRM, compared to the differentiation process of stem cells, is the most powerful component of the stem cell. That is, most of the healing properties of stem cells resides in the SRM. Equally important, the SRM from two or more stem cell types is used in the body’s natural healing processes. Each of the body’s many stem cell types release a unique set of molecules (SRM), and the combination of SRM from each unique stem cell type used by the body to heal a particular tissue is called S²RM®. Research shows us that within a particular tissue there are two or more stem cell types unique to that tissue, and that each of the stem cell types releases a unique pool of SRM. The unique individual pools of SRM that are combined to form S²RM® are critical for healing the particular tissue.

This past year has been pivotal for BRS, during which time we have begun our development programs for FDA approval of our S²RM®-based ALS therapeutic, and neurodegenerative diseases. Further, our skin and hair care technology and products have been out-licensed for world-wide distribution, and we maintain a rich pipeline of products for future FDA approvals, including our products for cataract, vaginal atrophy, diabetic ulcer and other wound conditions. Our research programs in cancer therapeutics, retinal degeneration, and antimicrobials continue, and is augmented through academic collaborations.

Meeting our future commercial and clinical product needs has meant that our manufacturing technology has been expanded and capacity has been scaled to meet long-term technology strategies and demand. Infrastructure improvements continue within our R&D and manufacturing facility to add both cell culture and stimulation capacity to support our fifteen clinical and commercial S²RM®-based products.

The therapeutics that we are developing or marketing help many patients who have few, if any, safe and effective options to treat their diseases or conditions. We are grateful to the patients, scientists, and physicians who participate in scientific studies and clinical trials to test experimental therapies for these debilitating diseases. Each and every individual in our company is dedicated to driving the continuation of our discoveries in the lab and the launch of new, best in class products to the marketplace.

Sincerely,

Dr. Greg Maguire, Ph.D.

Chief Scientific Officer, Founder

BioRegenerative Sciences, Inc.

 

References

Maguire G (2014) Systems biology approach to developing “systems therapeutics”. ACS Med Chem Lett. 2014 Mar 6;5(5):453-5. doi: 10.1021/ml5000614. eCollection 2014 May 8

Maguire G (2016) Therapeutics from Adult Stem Cells and the Hype Curve. ACS Med Chem Lett. 2016 Apr 25;7(5):441-3. doi: 10.1021/acsmedchemlett.6b00125. eCollection 2016 May 12.